{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T04:10:31Z","timestamp":1781928631204,"version":"3.54.5"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004756","name":"Emil Aaltosen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004212","name":"P\u00e4ivikki ja Sakari Sohlbergin S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hepatoblastoma is a rare pediatric liver malignancy usually treated with surgery and chemotherapy. To explore new treatment options for hepatoblastoma, drug screening was performed using six cell models established from aggressive hepatoblastoma tumors and healthy pediatric primary hepatocytes. Of the 527 screened compounds, 98 demonstrated cancer-selective activity in at least one hepatoblastoma model. The kinesin spindle protein (KSP) inhibitor filanesib was effective in all models and was further evaluated. Filanesib induced G2\/M arrest and apoptosis in hepatoblastoma cells at concentrations tolerable to primary hepatocytes. Prominent nuclear fragmentation was observed in filanesib-treated hepatoblastoma cells. Genes participating in cell cycle regulation were noted to be differentially expressed after filanesib treatment. Filanesib reduced the rate of tumor growth in 4\/5 hepatoblastoma mice models. One of these models showed complete growth arrest. Our results suggest that filanesib is a potential candidate for hepatoblastoma treatment and should be investigated in future clinical trials.<\/jats:p>","DOI":"10.1038\/s41698-025-00915-8","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T14:10:58Z","timestamp":1745590258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Functional screening identifies kinesin spindle protein inhibitor filanesib as a potential treatment option for hepatoblastoma"],"prefix":"10.1038","volume":"9","author":[{"given":"Ruth","family":"Nousiainen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Eloranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7306-7175","authenticated-orcid":false,"given":"Jani","family":"Saarela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9491-2868","authenticated-orcid":false,"given":"Antti","family":"Hassinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara J.","family":"Luck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Indersie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Potdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6094-9838","authenticated-orcid":false,"given":"Michaela J.","family":"Feodoroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouko","family":"Lohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lassi","family":"Paavolainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3125-2406","authenticated-orcid":false,"given":"Vilja","family":"Pieti\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Heikinheimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjut","family":"Pihlajoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"915_CR1","doi-asserted-by":"publisher","unstructured":"Feng, J. et al. Incidence trends and survival prediction of hepatoblastoma in children: A population-based study. Cancer Commun. 39, https:\/\/doi.org\/10.1186\/S40880-019-0411-7 (2019).","DOI":"10.1186\/S40880-019-0411-7"},{"key":"915_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/cncr.23169","volume":"112","author":"AM Linabery","year":"2008","unstructured":"Linabery, A. M. & Ross, J. A. Trends in childhood cancer incidence in the US. (1992-2004). Cancer 112, 416\u2013432 (2008).","journal-title":"Cancer"},{"key":"915_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/pbc.20122","volume":"43","author":"LG Spector","year":"2004","unstructured":"Spector, L. G., Feusner, J. H. & Ross, J. A. Hepatoblastoma and low birth weight. Pediatr. Blood Cancer 43, 706 (2004).","journal-title":"Pediatr. Blood Cancer"},{"key":"915_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jpeds.2005.04.019","volume":"147","author":"BA Hirschman","year":"2005","unstructured":"Hirschman, B. A., Pollock, B. H. & Tomlinson, G. E. The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. J. Pediatr. 147, 263\u2013266 (2005).","journal-title":"J. Pediatr."},{"key":"915_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/modpathol.3800977","volume":"21","author":"MC Curia","year":"2008","unstructured":"Curia, M. C. et al. Sporadic childhood hepatoblastomas show activation of b-catenin, mismatch repair defects and p53 mutations. Mod. Pathol. 21, 7\u201314 (2008).","journal-title":"Mod. Pathol."},{"key":"915_CR6","first-page":"83","volume":"10","author":"KE Nichols","year":"2001","unstructured":"Nichols, K. E., Malkin, D., Garber, J. E., Fraumeni, J. F. Jr & Li, F. P. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol. Biomark. Prev. 10, 83\u201387 (2001). Accessed October 3, 2023.","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"915_CR7","doi-asserted-by":"publisher","first-page":"91950","DOI":"10.18632\/oncotarget.20515","volume":"8","author":"SY Kim","year":"2017","unstructured":"Kim, S. Y. et al. Genomic profiles of a hepatoblastoma from a patient with Beckwith-Wiedemann syndrome with uniparental disomy on chromosome 11p15 and germline mutation of APC and PALB2. Oncotarget 8, 91950\u201391957 (2017).","journal-title":"Oncotarget"},{"key":"915_CR8","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/lt.21654","volume":"14","author":"MJ Finegold","year":"2008","unstructured":"Finegold, M. J. et al. Liver tumors: pediatric population. Liver Transpl. 14, 1545\u20131556 (2008).","journal-title":"Liver Transpl."},{"key":"915_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S1470-2045(16)30598-8","volume":"18","author":"RL Meyers","year":"2017","unstructured":"Meyers, R. L. et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children\u2019s Hepatic tumors International Collaboration. Lancet Oncol. 18, 122\u2013131 (2017).","journal-title":"Lancet Oncol."},{"key":"915_CR10","doi-asserted-by":"publisher","first-page":"21270","DOI":"10.1002\/cam4.6705","volume":"12","author":"AF Espinoza","year":"2023","unstructured":"Espinoza, A. F. et al. Navigating relapsed hepatoblastoma: predictive factors and surgical treatment strategy. Cancer Med. 12, 21270\u201321278 (2023).","journal-title":"Cancer Med."},{"key":"915_CR11","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1056\/NEJMoa1801109","volume":"378","author":"PR Brock","year":"2018","unstructured":"Brock, P. R. et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. N. Engl. J. Med. 378, 2376\u20132385 (2018).","journal-title":"N. Engl. J. Med."},{"key":"915_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/annonc\/mdf118","volume":"13","author":"LCM Kremer","year":"2002","unstructured":"Kremer, L. C. M., Van Dalen, E. C., Offringa, M. & Vo\u00fbte, P. A. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann. Oncol. 13, 503\u2013512 (2002).","journal-title":"Ann. Oncol."},{"key":"915_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Gr\u00f6bner","year":"2018","unstructured":"Gr\u00f6bner, S. N. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321\u2013327 (2018).","journal-title":"Nature"},{"key":"915_CR14","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jhep.2014.08.009","volume":"61","author":"M Eichenm\u00fcller","year":"2014","unstructured":"Eichenm\u00fcller, M. et al. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J. Hepatol. 61, 1312\u20131320 (2014).","journal-title":"J. Hepatol."},{"key":"915_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"F Yu","year":"2021","unstructured":"Yu, F., et al. Wnt\/\u03b2-catenin signaling in cancers and targeted therapies. Signal Transduct. Target. Ther. 6, 1\u201324 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"915_CR16","doi-asserted-by":"crossref","unstructured":"Kluiver, T. A. et al. Divergent WNT signaling and drug sensitivity profiles within hepatoblastoma tumors and organoids. Nat. Commun. 15, 8576 (2024).","DOI":"10.1038\/s41467-024-52757-w"},{"key":"915_CR17","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.18632\/oncotarget.27237","volume":"10","author":"D Kats","year":"2019","unstructured":"Kats, D. et al. Volasertib preclinical activity in high-risk hepatoblastoma. Oncotarget 10, 6403\u20136417 (2019).","journal-title":"Oncotarget"},{"key":"915_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. SLAS Discov. 4, 67\u201373 (1999).","journal-title":"SLAS Discov."},{"key":"915_CR19","doi-asserted-by":"publisher","unstructured":"Yadav, B. et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci. Rep. 4, https:\/\/doi.org\/10.1038\/SREP05193 (2014).","DOI":"10.1038\/SREP05193"},{"key":"915_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"915_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2020.09.026","volume":"141","author":"S Cairo","year":"2020","unstructured":"Cairo, S. et al. A combined clinical and biological risk classification improves prediction of outcome in hepatoblastoma patients. Eur. J. Cancer 141, 30\u201339 (2020).","journal-title":"Eur. J. Cancer"},{"key":"915_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.slasd.2023.03.002","volume":"28","author":"M Feodoroff","year":"2023","unstructured":"Feodoroff, M. et al. Comparison of two supporting matrices for patient-derived cancer cells in 3D drug sensitivity and resistance testing assay (3D-DSRT). SLAS Discov. 28, 138\u2013148 (2023).","journal-title":"SLAS Discov."},{"key":"915_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jconrel.2012.04.045","volume":"164","author":"G Mehta","year":"2012","unstructured":"Mehta, G., Hsiao, A. Y., Ingram, M., Luker, G. D. & Takayama, S. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J. Control Release 164, 192\u2013204 (2012).","journal-title":"J. Control Release"},{"key":"915_CR24","doi-asserted-by":"publisher","first-page":"110264","DOI":"10.1016\/j.msec.2019.110264","volume":"107","author":"JC Fontoura","year":"2020","unstructured":"Fontoura, J. C. et al. Comparison of 2D and 3D cell culture models for cell growth, gene expression and drug resistance. Mater. Sci. Eng. C. 107, 110264 (2020).","journal-title":"Mater. Sci. Eng. C."},{"key":"915_CR25","first-page":"910","volume":"14","author":"M Kapa\u0142czy\u0144ska","year":"2018","unstructured":"Kapa\u0142czy\u0144ska, M. et al. 2D and 3D cell cultures\u2014a comparison of different types of cancer cell cultures. Arch. Med. Sci. 14, 910\u2013919 (2018).","journal-title":"Arch. Med. Sci."},{"key":"915_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12092668","volume":"12","author":"JA Saltsman","year":"2020","unstructured":"Saltsman, J. A. et al. A Human organoid model of aggressive hepatoblastoma for disease modeling and drug testing. Cancers12, 1\u201318 (2020).","journal-title":"Cancers"},{"key":"915_CR27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jhep.2023.05.031","volume":"79","author":"A Claver\u00eda-Cabello","year":"2023","unstructured":"Claver\u00eda-Cabello, A. et al. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma. J. Hepatol. 79, 989\u20131005 (2023).","journal-title":"J. Hepatol."},{"key":"915_CR28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jhep.2024.01.003","volume":"80","author":"AF Espinoza","year":"2024","unstructured":"Espinoza, A. F. et al. A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J. Hepatol. 80, 610\u2013621 (2024).","journal-title":"J. Hepatol."},{"key":"915_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc2887","volume":"10","author":"J Trepel","year":"2010","unstructured":"Trepel, J., Mollapour, M., Giaccone, G. & Neckers, L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10, 537\u2013549 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"915_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ajpath.2022.10.006","volume":"193","author":"EH Hurley","year":"2023","unstructured":"Hurley, E. H. et al. Inhibition of heat shock factor 1 signaling decreases hepatoblastoma growth via induction of apoptosis. Am. J. Pathol. 193, 148\u2013160 (2023).","journal-title":"Am. J. Pathol."},{"key":"915_CR31","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jtho.2017.11.131","volume":"13","author":"E Felip","year":"2018","unstructured":"Felip, E. et al. Phase 2 study of the HSP-90 inhibitor AUY922 in previously treated and molecularly defined patients with advanced non\u2013small cell lung cancer. J. Thorac. Oncol. 13, 576\u2013584 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"915_CR32","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/ijc.31963","volume":"144","author":"G Augello","year":"2019","unstructured":"Augello, G. et al. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. Int J. Cancer 144, 2613\u20132624 (2019).","journal-title":"Int J. Cancer"},{"key":"915_CR33","doi-asserted-by":"publisher","first-page":"e30365","DOI":"10.1002\/pbc.30365","volume":"70","author":"PA Thompson","year":"2023","unstructured":"Thompson, P. A. et al. Vincristine\/irinotecan\/temsirolimus upfront window treatment of high-risk hepatoblastoma: a report from the Children\u2019s Oncology Group AHEP0731 Study Committee. Pediatr. Blood Cancer 70, e30365 (2023).","journal-title":"Pediatr. Blood Cancer"},{"key":"915_CR34","first-page":"2416","volume":"6","author":"E Mora","year":"2016","unstructured":"Mora, E., Lavoie Smith, E. M., Donohoe, C. & Hertz, D. L. Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am. J. Cancer Res. 6, 2416\u20132430 (2016). Accessed March 14, 2024.","journal-title":"Am. J. Cancer Res."},{"key":"915_CR35","doi-asserted-by":"publisher","unstructured":"Shahin R., Aljamal S. Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies. Future Sci. OA. 8, https:\/\/doi.org\/10.2144\/FSOA-2021-0116\/ASSET\/IMAGES\/LARGE\/FIGURE4.JPEG (2022).","DOI":"10.2144\/FSOA-2021-0116\/ASSET\/IMAGES\/LARGE\/FIGURE4.JPEG"},{"key":"915_CR36","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/359540a0","volume":"359","author":"KE Sawin","year":"1992","unstructured":"Sawin, K. E., Leguellec, K., Philippe, M. & Mitchison, T. J. Mitotic spindle organization by a plus-end-directed microtubule motor. Nature 359, 540\u2013543 (1992).","journal-title":"Nature"},{"key":"915_CR37","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1083\/jcb.123.3.665","volume":"123","author":"MMS Heck","year":"1993","unstructured":"Heck, M. M. S. et al. The kinesin-like protein KLP61F is essential for mitosis in Drosophila. J. Cell Biol. 123, 665\u2013679 (1993).","journal-title":"J. Cell Biol."},{"key":"915_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ydbio.2020.09.009","volume":"469","author":"MJ Konjikusic","year":"2021","unstructured":"Konjikusic, M. J., Gray, R. S. & Wallingford, J. B. The developmental biology of kinesins. Dev. Biol. 469, 26\u201336 (2021).","journal-title":"Dev. Biol."},{"key":"915_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/08880018.2021.1953655","volume":"39","author":"Y Luo","year":"2022","unstructured":"Luo, Y. et al. KIF11 as a potential cancer prognostic marker promotes tumorigenesis in children with Wilms tumor. Pediatr. Hematol. Oncol. 39, 145\u2013157 (2022).","journal-title":"Pediatr. Hematol. Oncol."},{"key":"915_CR40","doi-asserted-by":"publisher","first-page":"15609","DOI":"10.1007\/s00432-023-05240-w","volume":"149","author":"L Zhu","year":"2023","unstructured":"Zhu, L. et al. KIF11 serves as a cell cycle mediator in childhood acute lymphoblastic leukemia. J. Cancer Res. Clin. Oncol. 149, 15609\u201315622 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"915_CR41","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.bmcl.2005.02.055","volume":"15","author":"CD Cox","year":"2005","unstructured":"Cox, C. D. et al. Kinesin spindle protein (KSP) inhibitors. Part 1: the discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg. Med. Chem. Lett. 15, 2041\u20132045 (2005).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"915_CR42","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/1541-7786.MCR-11-0491","volume":"10","author":"Y Chen","year":"2012","unstructured":"Chen, Y., Chow, J. P. H. & Poon, R. Y. C. Inhibition of Eg5 acts synergistically with checkpoint abrogation in promoting mitotic catastrophe. Mol. Cancer Res. 10, 626\u2013635 (2012).","journal-title":"Mol. Cancer Res."},{"key":"915_CR43","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.3390\/cancers15204911","volume":"15","author":"SM Turaga","year":"2023","unstructured":"Turaga, S. M. et al. Inducing mitotic catastrophe as a therapeutic approach to improve outcomes in Ewing sarcoma. Cancers15, 4911 (2023).","journal-title":"Cancers"},{"key":"915_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.02.016","volume":"506","author":"G Jungwirth","year":"2021","unstructured":"Jungwirth, G. et al. KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. Cancer Lett. 506, 1\u201310 (2021).","journal-title":"Cancer Lett."},{"key":"915_CR45","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/ncb3486","volume":"19","author":"J Decarreau","year":"2017","unstructured":"Decarreau, J. et al. A tetrameric kinesin, Kif25, suppresses centrosome separation to establish proper spindle orientation. Nat. Cell Biol. 19, 384 (2017).","journal-title":"Nat. Cell Biol."},{"key":"915_CR46","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2011.11.020","volume":"147","author":"JZ Torres","year":"2011","unstructured":"Torres, J. Z. et al. The STARD9\/Kif16a kinesin associates with mitotic microtubules and regulates spindle pole assembly. Cell 147, 1309\u20131323 (2011).","journal-title":"Cell"},{"key":"915_CR47","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/cam4.4451","volume":"11","author":"D Pan","year":"2022","unstructured":"Pan, D. et al. Filanesib plus bortezomib and dexamethasone in relapsed\/refractory t(11;14) and 1q21 gain multiple myeloma. Cancer Med. 11, 358\u2013370 (2022).","journal-title":"Cancer Med."},{"key":"915_CR48","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1002\/cncr.30892","volume":"123","author":"JJ Shah","year":"2017","unstructured":"Shah, J. J. et al. A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed\/refractory multiple myeloma. Cancer 123, 4617\u20134630 (2017).","journal-title":"Cancer"},{"key":"915_CR49","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1002\/cncr.26664","volume":"118","author":"HJ Khoury","year":"2012","unstructured":"Khoury, H. J. et al. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer 118, 3556\u20133564 (2012).","journal-title":"Cancer"},{"key":"915_CR50","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/bjh.16788","volume":"192","author":"EM Ocio","year":"2021","unstructured":"Ocio, E. M. et al. Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib\/II Pomdefil clinical trial conducted by the Spanish MM group. Br. J. Haematol. 192, 522\u2013530 (2021).","journal-title":"Br. J. Haematol."},{"key":"915_CR51","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s10637-015-0211-0","volume":"33","author":"PM Lorusso","year":"2015","unstructured":"Lorusso, P. M. et al. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. Investig. New Drugs 33, 440\u2013449 (2015).","journal-title":"Investig. New Drugs"},{"key":"915_CR52","doi-asserted-by":"publisher","unstructured":"Hansson, K. et al. Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma. Sci. Transl. Med. 12, https:\/\/doi.org\/10.1126\/scitranslmed.aba4434 (2020).","DOI":"10.1126\/scitranslmed.aba4434"},{"key":"915_CR53","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/pbc.22609","volume":"55","author":"AK Souid","year":"2010","unstructured":"Souid, A. K. et al. A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children\u2019s Oncology Group phase I consortium study. Pediatr. Blood Cancer 55, 1323\u20131328 (2010).","journal-title":"Pediatr. Blood Cancer"},{"key":"915_CR54","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","volume":"36","author":"S Potdar","year":"2020","unstructured":"Potdar, S. et al. Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics 36, 3602\u20133604 (2020).","journal-title":"Bioinformatics"},{"key":"915_CR55","doi-asserted-by":"crossref","unstructured":"Chen, Y. et al. Robust scoring of selective drug responses for patient-tailored therapy selection. Nat. Protoc. 19, 60\u201382 (2024).","DOI":"10.1038\/s41596-023-00903-x"},{"key":"915_CR56","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-O","volume":"139","author":"I Nicoletti","year":"1991","unstructured":"Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F. & Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139, 271\u2013279 (1991).","journal-title":"J. Immunol. Methods"},{"key":"915_CR57","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ab.2012.10.010","volume":"433","author":"A G\u00fcrtler","year":"2013","unstructured":"G\u00fcrtler, A. et al. Stain-Free technology as a normalization tool in Western blot analysis. Anal. Biochem. 433, 105\u2013111 (2013).","journal-title":"Anal. Biochem"},{"key":"915_CR58","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/nprot.2016.105","volume":"11","author":"MA Bray","year":"2016","unstructured":"Bray, M. A. et al. Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nat. Protoc. 11, 1757\u20131774 (2016).","journal-title":"Nat. Protoc."},{"key":"915_CR59","doi-asserted-by":"publisher","first-page":"e2005970","DOI":"10.1371\/journal.pbio.2005970","volume":"16","author":"C McQuin","year":"2018","unstructured":"McQuin, C. et al. CellProfiler 3.0: next-generation image processing for biology. PLoS Biol. 16, e2005970 (2018).","journal-title":"PLoS Biol."},{"key":"915_CR60","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nbt.4314","volume":"37","author":"E Becht","year":"2018","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 37, 38\u201344 (2018).","journal-title":"Nat. Biotechnol."},{"key":"915_CR61","doi-asserted-by":"publisher","unstructured":"Nousiainen, R. et al. UBE2C expression is elevated in hepatoblastoma and correlates with inferior patient survival. Front. Genet. 14, https:\/\/doi.org\/10.3389\/FGENE.2023.1170940\/FULL (2023).","DOI":"10.3389\/FGENE.2023.1170940\/FULL"},{"key":"915_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-12-507","volume":"12","author":"MA Kallio","year":"2011","unstructured":"Kallio, M. A. et al. Chipster: user-friendly analysis software for microarray and other high-throughput data. BMC Genom. 12, 507 (2011).","journal-title":"BMC Genom."},{"key":"915_CR63","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357\u2013360 (2015).","journal-title":"Nat. Methods"},{"key":"915_CR64","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2013a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00915-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00915-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00915-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:02:54Z","timestamp":1745593374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00915-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["915"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-00915-8","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.I. is currently employed by the company XenTech. S.C. has formerly been employed by the company XenTech and is currently employed by the company Champions Oncology. No other competing interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}